Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

halozyme therapeutics inc. - HALO

HALO

Close Chg Chg %
73.23 -1.19 -1.63%

Closed Market

72.04

-1.19 (1.63%)

Volume: 2.97M

Last Updated:

Feb 19, 2026, 4:00 PM EDT

Trade Now

Company Overview: halozyme therapeutics inc. - HALO

HALO Key Data

Open

$73.94

 Day Range

71.05 - 73.94

52 Week Range

47.50 - 82.22

 Market Cap

$9.38B

Shares Outstanding

118.02M

 Public Float

116.58M

Beta

0.97

 Rev. Per Employee

N/A

P/E Ratio

28.63

 EPS

$2.61

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.13M

  

HALO Performance

1 Week
 
 -7.82%
 
1 Month
 
 2.84%
 
3 Months
 
 4.11%
 
1 Year
 
 26.81%
 
5 Years
 
 47.40%
 

HALO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About halozyme therapeutics inc. - HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

HALO At a Glance

Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego, California 92130
Phone 1-858-794-8889 Revenue 1.02B
Industry Biotechnology Net Income 444.09M
Sector Health Technology 2024 Sales Growth 22.438%
Fiscal Year-end 12 / 2025 Employees 350
View SEC Filings

HALO Valuation

P/E Current 28.633
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 13.933
Price to Sales Ratio 6.094
Price to Book Ratio 16.182
Price to Cash Flow Ratio 12.92
Enterprise Value to EBITDA 11.265
Enterprise Value to Sales 7.021
Total Debt to Enterprise Value 0.216

HALO Efficiency

Revenue/Employee 2,900,925.714
Income Per Employee 1,268,831.429
Receivables Turnover 3.292
Total Asset Turnover 0.521

HALO Liquidity

Current Ratio 7.803
Quick Ratio 6.783
Cash Ratio 4.285

HALO Profitability

Gross Margin 77.301
Operating Margin 54.315
Pretax Margin 54.872
Net Margin 43.739
Return on Assets 22.791
Return on Equity 198.419
Return on Total Capital 23.369
Return on Invested Capital 25.315

HALO Capital Structure

Total Debt to Total Equity 422.324
Total Debt to Total Capital 80.855
Total Debt to Total Assets 71.007
Long-Term Debt to Equity 420.386
Long-Term Debt to Total Capital 80.484
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Halozyme Therapeutics Inc. - HALO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
443.31M 660.12M 829.25M 1.02B
Sales Growth
+65.67% +48.91% +25.62% +22.44%
Cost of Goods Sold (COGS) incl D&A
81.41M 182.45M 266.13M 230.47M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.00M 49.64M 84.86M 81.31M
Depreciation
3.00M 6.49M 11.08M 10.26M
Amortization of Intangibles
- 43.15M 73.77M 71.05M
COGS Growth
+87.73% +124.11% +45.87% -13.40%
Gross Income
361.90M 477.66M 563.12M 784.86M
Gross Income Growth
+61.40% +31.99% +17.89% +39.38%
Gross Profit Margin
+81.64% +72.36% +67.91% +77.30%
2021 2022 2023 2024 5-year trend
SG&A Expense
86.00M 188.23M 225.54M 233.38M
Research & Development
35.67M 66.61M 76.36M 79.05M
Other SG&A
50.32M 121.63M 149.18M 154.34M
SGA Growth
+7.53% +118.89% +19.82% +3.48%
Other Operating Expense
- - - -
-
Unusual Expense
- 20.96M 24.61M (13.20M)
EBIT after Unusual Expense
254.94M 264.82M 350.77M 551.48M
Non Operating Income/Expense
1.10M 1.05M 16.32M 23.75M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
7.53M 16.95M 18.76M 18.09M
Interest Expense Growth
-63.07% +125.18% +10.71% -3.56%
Gross Interest Expense
7.53M 16.95M 18.76M 18.09M
Interest Capitalized
- - - -
-
Pretax Income
248.52M 248.92M 348.33M 557.13M
Pretax Income Growth
+92.20% +0.16% +39.94% +59.94%
Pretax Margin
+56.06% +37.71% +42.01% +54.87%
Income Tax
(154.19M) 46.79M 66.73M 113.04M
Income Tax - Current - Domestic
1.24M 8.68M 30.68M 111.90M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(155.43M) 38.11M 36.05M 1.14M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
402.71M 202.13M 281.59M 444.09M
Minority Interest Expense
- - - -
-
Net Income
402.71M 202.13M 281.59M 444.09M
Net Income Growth
+211.97% -49.81% +39.31% +57.71%
Net Margin Growth
+90.84% +30.62% +33.96% +43.74%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
402.71M 202.13M 281.59M 444.09M
Preferred Dividends
- - - -
-
Net Income Available to Common
402.71M 202.13M 281.59M 444.09M
EPS (Basic)
2.8633 1.4771 2.1345 3.5016
EPS (Basic) Growth
+202.13% -48.41% +44.51% +64.05%
Basic Shares Outstanding
140.65M 136.84M 131.93M 126.83M
EPS (Diluted)
2.7433 1.4375 2.0984 3.4313
EPS (Diluted) Growth
+200.64% -47.60% +45.98% +63.52%
Diluted Shares Outstanding
146.80M 140.61M 134.20M 129.42M
EBITDA
278.90M 339.07M 422.43M 632.79M
EBITDA Growth
+89.03% +21.58% +24.58% +49.80%
EBITDA Margin
+62.91% +51.37% +50.94% +62.32%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 78.00
Number of Ratings 9 Current Quarters Estimate 1.528
FY Report Date 03 / 2026 Current Year's Estimate 8.016
Last Quarter’s Earnings -0.24 Median PE on CY Estimate N/A
Year Ago Earnings 4.15 Next Fiscal Year Estimate 9.848
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 4
Mean Estimate 1.53 1.80 8.02 9.85
High Estimates 1.59 1.91 8.21 10.08
Low Estimate 1.40 1.68 7.87 9.48
Coefficient of Variance 4.82 4.94 1.78 2.65

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 6 6
OVERWEIGHT 0 0 0
HOLD 3 3 4
UNDERWEIGHT 0 0 0
SELL 1 1 0
MEAN Overweight Overweight Overweight

Insider Actions for Halozyme Therapeutics Inc. - HALO

Date Name Shares Transaction Value
Apr 2, 2025 Jeffrey William Henderson Director 33,108 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $64.05 per share 2,120,567.40
Feb 28, 2025 Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER 186,153 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.01 per share 10,798,735.53
Feb 28, 2025 Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER 185,453 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.67 per share 10,880,527.51
Feb 28, 2025 Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER 176,053 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.09 per share 10,226,918.77
Feb 28, 2025 Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER 175,453 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.65 per share 10,290,318.45
Feb 28, 2025 Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER 173,856 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.25 per share 10,127,112.00
Feb 28, 2025 Michael J. LaBarre SVP, CHIEF TECHNICAL OFFICER 173,756 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $58.74 per share 10,206,427.44
Feb 24, 2025 Helen I. Torley PRESIDENT AND CEO; Director 71,038 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Helen I. Torley PRESIDENT AND CEO; Director 67,027 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Mark Snyder SVP, CHIEF LEGAL OFFICER 22,603 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Mark Snyder SVP, CHIEF LEGAL OFFICER 21,327 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER 22,603 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER 21,327 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Halozyme Therapeutics Inc. in the News